Cargando…
Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study
BACKGROUND: α-fetoprotein (AFP) response has been proven a key tumor marker for hepatocellular carcinoma (HCC), but its definition remains controversial. This study aims to characterize AFP trajectories after transarterial chemoembolization (TACE) and examine its impact on clinical outcomes. METHODS...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035711/ https://www.ncbi.nlm.nih.gov/pubmed/35480077 http://dx.doi.org/10.1016/j.eclinm.2022.101391 |
_version_ | 1784693356944687104 |
---|---|
author | Lu, Linbin Shen, Lujun Wu, Zhixian Shi, Yanhong Hou, Peifeng Xue, Zengfu Lin, Cheng Chen, Xiong |
author_facet | Lu, Linbin Shen, Lujun Wu, Zhixian Shi, Yanhong Hou, Peifeng Xue, Zengfu Lin, Cheng Chen, Xiong |
author_sort | Lu, Linbin |
collection | PubMed |
description | BACKGROUND: α-fetoprotein (AFP) response has been proven a key tumor marker for hepatocellular carcinoma (HCC), but its definition remains controversial. This study aims to characterize AFP trajectories after transarterial chemoembolization (TACE) and examine its impact on clinical outcomes. METHODS: This longitudinal, multicenter, retrospective, cohort study examined data from the electronic medical record system of four hospitals in China between January 1, 2007 to December 31, 2016. A latent class growth mixed model was applied to distinguish potential AFP dynamic changing trajectories. The multivariable Cox models were used to calculate adjusted hazard ratios (aHRs) and 95% CIs for overall survival. Inverse-probability-of-treatment weighted analyses were performed to eliminate unmeasured confounders through marginal structural models. FINDINGS: A total of 881 patients, who had intermediate-stage HCC with AFP repeatedly measured 3 to 10 times, were included in the study. Three distinct trajectories were identified using the latent class growth mixture model: high-rising (25.7%; n = 226), low-stable (58.7%; n = 517), and sharp-falling (AFP serological response, 15.6%; n = 138). Compared with the low-stable class, the aHRs for death were 5.13 (3.71, 7.10) and 0.52 (0.33, 0.81) for the high-rising and sharp-falling class, adjusted by gender, baseline major tumor size, intrahepatic lesions number, and logAFP(smooth). Furthermore, high-rising class had a significantly higher HR in the subgroup of female patients (10.60, 95%CI: 6.29, 17.86), age<55 (6.78, 95%CI: 4.79, 9.59) and Child-Pugh class B (23.01, 95%CI:8.07, 65.63) (P = 0.014, 0.046 and 0.033 for interaction, respectively). Trajectories of AFP had the highest relative importance of each parameter to survival, including largest tumor size, intrahepatic lesions number, Child-Pugh class, and baseline AFP. INTERPRETATION: AFP trajectories were associated with overall survival for intermediate-stage HCC after TACE. FUNDING: The Natural Science Foundation of Fujian Province (Nos. 2018J01352, 2016J01576 and 2016J01586); the Science and Technology Innovation Joint Foundation of Fujian Province (Nos. 2017Y9125). |
format | Online Article Text |
id | pubmed-9035711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-90357112022-04-26 Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study Lu, Linbin Shen, Lujun Wu, Zhixian Shi, Yanhong Hou, Peifeng Xue, Zengfu Lin, Cheng Chen, Xiong EClinicalMedicine Articles BACKGROUND: α-fetoprotein (AFP) response has been proven a key tumor marker for hepatocellular carcinoma (HCC), but its definition remains controversial. This study aims to characterize AFP trajectories after transarterial chemoembolization (TACE) and examine its impact on clinical outcomes. METHODS: This longitudinal, multicenter, retrospective, cohort study examined data from the electronic medical record system of four hospitals in China between January 1, 2007 to December 31, 2016. A latent class growth mixed model was applied to distinguish potential AFP dynamic changing trajectories. The multivariable Cox models were used to calculate adjusted hazard ratios (aHRs) and 95% CIs for overall survival. Inverse-probability-of-treatment weighted analyses were performed to eliminate unmeasured confounders through marginal structural models. FINDINGS: A total of 881 patients, who had intermediate-stage HCC with AFP repeatedly measured 3 to 10 times, were included in the study. Three distinct trajectories were identified using the latent class growth mixture model: high-rising (25.7%; n = 226), low-stable (58.7%; n = 517), and sharp-falling (AFP serological response, 15.6%; n = 138). Compared with the low-stable class, the aHRs for death were 5.13 (3.71, 7.10) and 0.52 (0.33, 0.81) for the high-rising and sharp-falling class, adjusted by gender, baseline major tumor size, intrahepatic lesions number, and logAFP(smooth). Furthermore, high-rising class had a significantly higher HR in the subgroup of female patients (10.60, 95%CI: 6.29, 17.86), age<55 (6.78, 95%CI: 4.79, 9.59) and Child-Pugh class B (23.01, 95%CI:8.07, 65.63) (P = 0.014, 0.046 and 0.033 for interaction, respectively). Trajectories of AFP had the highest relative importance of each parameter to survival, including largest tumor size, intrahepatic lesions number, Child-Pugh class, and baseline AFP. INTERPRETATION: AFP trajectories were associated with overall survival for intermediate-stage HCC after TACE. FUNDING: The Natural Science Foundation of Fujian Province (Nos. 2018J01352, 2016J01576 and 2016J01586); the Science and Technology Innovation Joint Foundation of Fujian Province (Nos. 2017Y9125). Elsevier 2022-04-16 /pmc/articles/PMC9035711/ /pubmed/35480077 http://dx.doi.org/10.1016/j.eclinm.2022.101391 Text en © 2022 The Author(s) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Articles Lu, Linbin Shen, Lujun Wu, Zhixian Shi, Yanhong Hou, Peifeng Xue, Zengfu Lin, Cheng Chen, Xiong Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study |
title | Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study |
title_full | Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study |
title_fullStr | Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study |
title_full_unstemmed | Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study |
title_short | Trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: A longitudinal, retrospective, multicentre, cohort study |
title_sort | trajectories of serum α-fetoprotein and intermediate-stage hepatocellular carcinoma outcomes after transarterial chemoembolization: a longitudinal, retrospective, multicentre, cohort study |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9035711/ https://www.ncbi.nlm.nih.gov/pubmed/35480077 http://dx.doi.org/10.1016/j.eclinm.2022.101391 |
work_keys_str_mv | AT lulinbin trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy AT shenlujun trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy AT wuzhixian trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy AT shiyanhong trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy AT houpeifeng trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy AT xuezengfu trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy AT lincheng trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy AT chenxiong trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy AT trajectoriesofserumafetoproteinandintermediatestagehepatocellularcarcinomaoutcomesaftertransarterialchemoembolizationalongitudinalretrospectivemulticentrecohortstudy |